[1]LIU J,DONG L,ZHU Y,et al.Prostate cancer treatment-China's perspective[J].Cancer Lett,2022 ,550:215927.
[2]邓姣,马金鹏,杨德林.前列腺癌早期诊断的研究进展[J].现代肿瘤医学,2022,30(05):903-907.
DENG J,MA JP,YANG DL.Research progress of early diagnosis of prostate cancer [J].Modern Oncology,2022,30(05):903-907.
[3]SEKHOACHA M,RIET K,MOTLOUNG P,et al.Prostate cancer review:Genetics,diagnosis,treatment options,and alternative approaches[J].Molecules,2022,27(17):5730.
[4]陈旭儿,黄月英,吴晓环.前列腺癌患者ADT治疗癌因性疲劳状态影响因素及运动训练的干预效果分析[J].基层医学论坛,2021,25(33):4772-4774.
CHEN XE,HUANG YY,WU XH.Analysis of the influencing factors of cancer-related fatigue state and the intervention effect of exercise training by ADT in patients with prostate cancer [J].The Medical Forum,2021,25(33):4772-4774.
[5]SUN Y,LI S,YU W,et al.CD148 serves as a prognostic marker of gastric cancer and hinders tumor progression by dephosphorylating EGFR [J].J Cancer,2020,11(9):2667-2678.
[6]HE L,TAKAHASHI K,PASIC L,et al.The effects of CD148 Q276P/R326Q polymorphisms in A431D epidermoid cancer cell proliferation and epidermal growth factor receptor signaling [J].Cancer Rep(Hoboken),2022,5(9):e1566.
[7]SPRING K,FOURNIER P,LAPOINTE L,et al.The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis [J].Oncogene,2015,34(44):5536-5547.
[8]RUIVENKAMP CA,VAN WEZEL T,ZANON C,et al.Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers [J].Nat Genet,2002,31(3):295-300.
[9]FOURNIER P,DUSSAULT S,FUSCO A,et al.Tyrosine phosphatase PTPRJ/DEP-1 is an essential promoter of vascular permeability,angiogenesis,and tumor progression [J].Cancer Res,2016,76(17):5080-5091.
[10]CHABOT C,SPRING K,GRATTON JP,et al.New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival[J].Mol Cell Biol,2009,29(1):241-253.
[11]杨松,刘修恒.转移性去势抵抗性前列腺癌的药物治疗进展[J].医学研究杂志,2022,51(11):4-9.
YANG S,LIU XH.Advances in drug therapy for metastatic castration-resistant prostate cancer [J].Journal of Medical Research,2022,51(11):4-9.
[12]刘贤,龙慧民.去势抵抗性前列腺癌治疗进展[J].现代实用医学,2021,33(07):974-977.
LIU X,LONG HM.Advances in the treatment of castration-resistant prostate cancer [J].Modern Practical Medicine,2021,33(07):974-977.
[13]YAN CM,ZHAO YL,CAI HY,et al.Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A [J].Oncol Rep,2015,33(4):1737-1744.
[14]LI H,ZHANG P,LIU C,et al.The structure,function and regulation of protein tyrosine phosphatase receptor type J and its role in diseases [J].Cells,2022(1):8.
[15]SENIS YA,NAGY Z,MORI J,et al.Platelet Src family kinases:A tale of reversible phosphorylation [J].Res Pract Thromb Haemost,2021,5(3):376-389.
[16]GUARDIA T,ZHANG Y,THOMPSON KN,et al.OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer[J].Proc Natl Acad Sci USA,2023,120(11):e2215553120.
[17]JIN R,LUO Z,JUN-LI,et al.USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis,immune infiltration and chemotherapy resistance[J].Front Oncol,2023,13:1023292.
[18]LUO J,ZOU H,GUO Y,et al.SRC kinase-mediated signaling pathways and targeted therapies in breast cancer[J].Breast Cancer Res,2022,24(1):99.
[19]陈蕾,柳玉红,邹桂华,等.FAK和Src在甲状腺乳头状癌中的表达及其在肿瘤侵袭转移中的临床意义及机制研究[J].现代肿瘤医学,2017,25(6):876-880.
CHEN L,LIU YH,ZOU GH,et al.The clinical significance and mechanism research of FAK and Src expression in the process of invasion and metastases in papillary thyroid carcinoma[J].Modern Oncology,2017,25(6):876-880.
[20]MIGLIACCIO A,DI DOMNICO M,CASTORIA G,et al.Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells:steroid antagonist action [J].Cancer Res,2005,65(22):10585-10593.
[21]MASUD N,ALDAHISH A,ICZKOWSKI KA,et al.Zinc finger protein-like 1 is a novel neuroendocrine biomarker for prostate cancer[J].Int J Oncol,2023,62(3):38.
[22]RAITH F,O' DONOVAN DH,LEMOS C,et al.Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment[J].Int J Mol Sci,2023,24(3):2289.
[23]ZHANG XF,TU R,LI K,et al.Tumor suppressor PTPRJ is a target of miR-155 in colorectal cancer[J].J Cell Biochem,2017,118(10):3391-3400.